Actis GC, Pellicano R. Inflammatory bowel disease: Efficient remission maintenance is crucial for cost containment. World J Gastrointest Pharmacol Ther 2017; 8(2): 114-119 [PMID: 28533920 DOI: 10.4292/wjgpt.v8.i2.114]
Corresponding Author of This Article
Giovanni C Actis, MD, the Medical Center Practice Office, 10129 Torino, Italy. actis_g@libero.it
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Minireviews
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastrointest Pharmacol Ther. May 6, 2017; 8(2): 114-119 Published online May 6, 2017. doi: 10.4292/wjgpt.v8.i2.114
Inflammatory bowel disease: Efficient remission maintenance is crucial for cost containment
Giovanni C Actis, Rinaldo Pellicano
Giovanni C Actis, Rinaldo Pellicano, the Medical Center Practice Office, 10129 Torino, Italy
Giovanni C Actis, Hepatogastroenterology Division, Ospedale Gradenigo, Corso Regina Margherita, 10153 Torino, Italy
Rinaldo Pellicano, Unit of Gastroenterology, Ospedale Molinette, 10126 Torino, Italy
Author contributions: Actis GC and Pellicano R shared responsibility in study design, manuscript development, and literature search; Pellicano R double-checked the references and formatted the paper.
Conflict-of-interest statement: The authors declare no potential conflicts of interest and no financial support.
Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Correspondence to: Giovanni C Actis, MD, the Medical Center Practice Office, 10129 Torino, Italy. actis_g@libero.it
Telephone: +39-011-591388 Fax: +39-011-505564
Received: July 27, 2016 Peer-review started: July 29, 2016 First decision: October 20, 2016 Revised: October 28, 2016 Accepted: January 11, 2017 Article in press: January 13, 2017 Published online: May 6, 2017
Core Tip
Core tip: Cost-effective maintenance of remission of inflammatory bowel diseases (IBD) is a traditionally unsolved challenge for care-takers and budget supervisors. The newly released (biologic) formulations, though purported to act as disease terminators, have failed to pay back their initial cost. We have faced the issue by reappraising initial simple tenets and found the following: (1) usually, uncomplicated IBD rests in remission by using cheap traditional drugs, provided the indication is correct, and, chiefly, that adherence is tightly maintained. Non compliant IBD patients cost manifold the compliant ones, and are the main cause of budget distortion; and (2) third-party drugs (nonsteroidal anti-inflammatory drugs, e.g., should be avoided. A frozen steady-state is the regime to effectively maintain IBD.
